New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
04:55 EDTA, A, A, A, RHHBY, RHHBY, RHHBY, RHHBY, PKI, PKI, PKI, PKI, LIFE, LIFE, LIFE, LIFE, ILMN, ILMN, ILMN, ILMN, QGEN, QGEN, QGEN, QGEN, PACB, PACB, PACB, PACBG Corp to host a meeting
14th Annual Advances in Genome Biology and Technology Meeting is being held on Marco Island, Florida on February 20-23.
News For A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 12, 2015
14:47 EDTILMNIllumina sees FY15 EPS $3.12-$3.18, consensus $3.17
Sees FY15 20% revenue growth of 20%, consensus $2.26B.
14:45 EDTILMNIllumina sees Q4 EPS 'slightly above' high end of prior view
Subscribe for More Information
14:42 EDTILMNIllumina options active on guidance
Subscribe for More Information
14:42 EDTILMNLockheed Martin, Illumina announce strategic alliance
Subscribe for More Information
14:09 EDTILMNIllumina sees FY15 revenue growth of 20%, consensus $2.26B
Guidance issued during presentation at JPMorgan Healthcare Conference.
14:08 EDTILMNIllumina sees Q4 revenue $512M, consensus $503.83M
Subscribe for More Information
12:46 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
09:31 EDTQGENTokai Pharmaceuticals announces collaboration with QIAGEN
Subscribe for More Information
09:10 EDTADako, Cell Signaling Technology announce partnership
Dako, an Agilent Technologies company, and Cell Signaling Technology, or CST, a worldwide provider of antibodies, announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. The financial details of the agreement were not disclosed.
09:04 EDTAAgilent's Dako unit, Cell Signaling Technology announce strategic partnership
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. The financial details of the agreement were not disclosed.
08:37 EDTRHHBYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06:40 EDTRHHBYFoundation Medicine to host conference call
Subscribe for More Information
05:36 EDTQGENQIAGEN announces regulatory registration of lung cancer companion diagnostic
Subscribe for More Information
05:25 EDTRHHBYFoundation Medicine up 100.6% following transaction with Roche
05:22 EDTRHHBYFoundation Medicine announces strategic collaboration with Roche
Subscribe for More Information
05:21 EDTRHHBYRoche to acquire majority interest in Foundation Medicine for $50 per share
Subscribe for More Information
January 11, 2015
19:29 EDTILMNUniversities of Edinburgh, Glasgow partner with Illumina
Subscribe for More Information
15:20 EDTQGENQIAGEN expects to meet 2014 guidance ex-charges
Subscribe for More Information
15:16 EDTQGENQIAGEN to take Q4 charges of $41M for acquisition, restructuring
QIAGEN said that following its acquisition of the Enzyme Solutions Unit from Enzymatics, it will take a business integration and acquisition-related pre-tax charge on operating income in Q4 of approximately $21M, or 6c per share of adjusted diluted EPS, and of which $18M are non-cash items. These charges, which will be excluded from adjusted results, involve actions to reduce overlapping activities and sites, including the closing of the Gaithersburg, Maryland, site. In addition, following a review to further improve efficiency and effectiveness, QIAGEN will now take a restructuring-related pre-tax charge on operating income in Q4 of approximately $26M, or 8 per share, of which $20M are non-cash items. In line with QIAGEN's policy, the restructuring charges, which primarily involve the impairment of various technology-related assets, will not be excluded from adjusted results.
15:12 EDTQGENQIAGEN acquires Enzyme Solutions Unit of Enzymatics
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use